Fracture Prediction, Imaging and Screening in Osteoporosis

Overview

Journal Nat Rev Endocrinol

Specialty Endocrinology

Date 2019 Jun 14

PMID 31189982

Citations 69

Authors

Nicholas R Fuggle

Elizabeth M Curtis

Kate A Ward

Nicholas C Harvey

Elaine M Dennison

Cyrus Cooper

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is associated with increased fragility of bone and a subsequent increased risk of fracture. The diagnosis of osteoporosis is intimately linked with the imaging and quantification of bone and BMD. Scanning modalities, such as dual-energy X-ray absorptiometry or quantitative CT, have been developed and honed over the past half century to provide measures of BMD and bone microarchitecture for the purposes of clinical practice and research. Combined with fracture prediction tools such as Fracture Risk Assessment Tool (FRAX) (which use a combination of clinical risk factors for fracture to provide a measure of risk), these elements have led to a paradigm shift in the ability to diagnose osteoporosis and predict individuals who are at risk of fragility fracture. Despite these developments, a treatment gap exists between individuals who are at risk of osteoporotic fracture and those who are receiving therapy. In this Review, we summarize the epidemiology of osteoporosis, the history of scanning modalities, fracture prediction tools and future directions, including the most recent developments in prediction of fractures.

Citing Articles

Radiofrequency Echographic Multi Spectrometry-A Novel Tool in the Diagnosis of Osteoporosis and Prediction of Fragility Fractures: A Systematic Review.

Icatoiu E, Vladulescu-Trandafir A, Groseanu L, Berghea F, Cobilinschi C, Potcovaru C Diagnostics (Basel). 2025; 15(5).

PMID: 40075802 PMC: 11898608. DOI: 10.3390/diagnostics15050555.

Establishing the effect of computed tomography reconstruction kernels on the measure of bone mineral density in opportunistic osteoporosis screening.

Matheson B, Boyd S Sci Rep. 2025; 15(1):5449.

PMID: 39953113 PMC: 11828980. DOI: 10.1038/s41598-025-88551-x.

Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors.

Ye C, Zhao B, Leslie W, Ruiz J, Zhao H, Abdel-Wahab N BMJ Oncol. 2025; 3(1):e000398.

PMID: 39886118 PMC: 11347678. DOI: 10.1136/bmjonc-2024-000398.

Assessment of trabecular bone Hounsfield units in the lumbar spine for osteoporosis evaluation in individuals aged 65 and above: a review.

Alharthy A Osteoporos Int. 2024; 36(2):225-233.

PMID: 39738829 DOI: 10.1007/s00198-024-07340-w.

Targeting NAMPT-OPA1 for treatment of senile osteoporosis.

Bai C, Tian B, Zhang M, Qin Q, Shi X, Yang X Aging Cell. 2024; 24(3):e14400.

PMID: 39543818 PMC: 11896342. DOI: 10.1111/acel.14400.

References

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J . Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations.... Arch Osteoporos. 2013; 8:136. PMC: 3880487. DOI: 10.1007/s11657-013-0136-1. View

Gullberg B, Johnell O, Kanis J . World-wide projections for hip fracture. Osteoporos Int. 1997; 7(5):407-13. DOI: 10.1007/pl00004148. View

Cooper C, Campion G, Melton 3rd L . Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992; 2(6):285-9. DOI: 10.1007/BF01623184. View

Chrischilles E, Butler C, Davis C, Wallace R . A model of lifetime osteoporosis impact. Arch Intern Med. 1991; 151(10):2026-32. View

Sambrook P, Cooper C . Osteoporosis. Lancet. 2006; 367(9527):2010-8. DOI: 10.1016/S0140-6736(06)68891-0. View

van der Velde R, Wyers C, Curtis E, Geusens P, van den Bergh J, de Vries F . Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporos Int. 2016; 27(11):3197-3206. PMC: 5035540. DOI: 10.1007/s00198-016-3650-3. View

Cooper C, Cole Z, Holroyd C, Earl S, Harvey N, Dennison E . Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011; 22(5):1277-88. PMC: 3546313. DOI: 10.1007/s00198-011-1601-6. View

Kanis J, Oden A, McCloskey E, Johansson H, Wahl D, Cooper C . A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012; 23(9):2239-56. PMC: 3421108. DOI: 10.1007/s00198-012-1964-3. View

Curtis E, van der Velde R, Moon R, van den Bergh J, Geusens P, de Vries F . Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status. Bone. 2016; 87:19-26. PMC: 4890652. DOI: 10.1016/j.bone.2016.03.006. View

10.

Cummings S, Melton L . Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359(9319):1761-7. DOI: 10.1016/S0140-6736(02)08657-9. View

11.

Bliuc D, Alarkawi D, Nguyen T, Eisman J, Center J . Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res. 2014; 30(4):637-46. DOI: 10.1002/jbmr.2393. View

12.

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

13.

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

14.

Kanis J, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L . SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013; 8:144. PMC: 3880480. DOI: 10.1007/s11657-013-0144-1. View

15.

CHAPUY M, Arlot M, Duboeuf F, Brun J, Crouzet B, Arnaud S . Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992; 327(23):1637-42. DOI: 10.1056/NEJM199212033272305. View

16.

Dawson-Hughes B, Harris S, Krall E, Dallal G . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997; 337(10):670-6. DOI: 10.1056/NEJM199709043371003. View

17.

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View

18.

Roux C, Reginster J, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z . Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res. 2006; 21(4):536-42. DOI: 10.1359/jbmr.060101. View

19.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

20.

Hodsman A, Hanley D, Josse R . Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ. 2002; 166(11):1426-30. PMC: 111217. View